Biallelic ZNF142-null mutations in patients with early-onset generalized dystonia
Objective: To identify a novel genetic factor contributing to the phenotypic expression of early-onset generalized dystonia. Background: To date, only about 20-30% of cases with…Atypical presentation of Dopa-responsive dystonia- late onset with severe swallowing difficulty
Objective: To learn about atypical presentation of Dopa-responsive dystonia (DRD) and give correct diagnose in time. Background: DRD compasses a group of clinically and genetically…Associated movements disorders to Hereditary Spastic Paraplegia (HSP) in a case series from South Spain
Objective: Describe different movement disorders associated with HSP in a series from the south Spain. Background: HSP englobe a heterogeneous group of diseases. Different movement…Comparative Study of Dry Needling under Ultrasound Guidance and Extracorporeal Shock Wave Therapy for Myofascial Pain and Spasticity Management
Objective: The aim was to conduct comparative study of using dry needling under ultrasound guidance vs ESWT for detecting MTrP and myofascial pain and spasticity…OnabotulinumtoxinA treatment in adults with spasticity reduces caregiver burden: Results from the ASPIRE study
Objective: To examine the impact of onabotulinumtoxinA treatment in adult patients with spasticity on caregiver burden over 2 years from the Adult Spasticity International Registry…Clinical Characteristics that Impact OnabotulinumtoxinA Treatment Adherence in Patients with Spasticity from ASPIRE
Objective: To identify patient demographics and clinical characteristics that impact onabotulinumtoxinA treatment adherence from the Adult Spasticity International Registry (ASPIRE) study. Background: A better understanding…An examination of real-world onabotulinumtoxinA utilisation for the treatment of lower limb spasticity: The Adult Spasticity International Registry (ASPIRE) study
Objective: To explore real-world patterns of onabotulinumtoxinA utilisation in patients with lower limb spasticity over 2 years. Background: OnabotulinumtoxinA treatment for spasticity is variable as…Goal setting for botulinum toxin injections: Impact of the Upper Limb International Spasticity (ULIS) programme
Objective: The Upper Limb International Spasticity (ULIS) programme is a series of observational cohort studies across >30 countries. This analysis explores changes in goal setting…AbobotulinumtoxinA: evidence for long duration of response
Objective: To assess clinical treatment intervals and duration of response for abobotulinumtoxinA in the management of pediatric and adult spasticity and assess preclinical data that…An examination of real-world onabotulinumtoxinA utilization for the treatment of upper limb spasticity: The Adult Spasticity International Registry (ASPIRE) study
Objective: To explore real-world patterns of onabotulinumtoxinA utilization in patients with upper limb spasticity over 2 years. Background: OnabotulinumtoxinA treatment for spasticity is variable, as…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.